Denali Therapeutics, Inc. (DNLI)

17.98 +0.61 (+3.51%) USD  |  NASDAQ  |  Dec 12, 16:00
17.98 0.00 (0.00%) After-Hours: 20:00
More

Denali Therapeutics Research and Development Expense (TTM): 420.66M for Sept. 30, 2025

Research and Development Expense (TTM) Chart

View Research and Development Expense (TTM) for DNLI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Novavax, Inc. 369.02M
Agenus, Inc. 105.60M
AIM ImmunoTech, Inc. 3.826M
Protalix Biotherapeutics, Inc. 18.06M
Armata Pharmaceuticals, Inc. 26.10M